Drug Trial Radar · NCT05415072
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
66
Actual
Start
Jul 4, 2022
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.
Conditions
- Metastatic Uveal Melanoma
Interventions
DYP688Drug
Single agent DYP688
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I (Dose Escalation): Incidence and severity of dose limiting toxicities (DLTs) during the first 28 days of treatment.Time frame: 28 days
- Phase I (Dose Escalation): Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: 9 months
- Phase I (Dose Escalation): Frequency of dose interruptions, reductions, and discontinuationsTime frame: 9 months
- Phase II: Overall Response rate (ORR) per RECIST 1.1Time frame: 17 months
Locations
11 sites in 7 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Columbia University Medical Center
New York, New York
Memorial Sloane Ketterin Cancer Ctr
New York, New York
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Leiden, South Holland, Netherlands
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.